Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 40 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SABU PHARMA from Antwerpen, company number BE1021744847, closed financial year 2025 with a result of € 16,544 after tax. For that financial year SABU PHARMA recorded a gross margin of € 37,671 and equity of € 19,544. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 15, 2026.
€ 19,544
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 16,544
Profit after tax over the fiscal year.
€ 15,218
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 16,544.
Debts at end 2025
€ 482,900
€ 30,377 is repaid this year. At this pace the long-term loan is gone in ≈ 16 years.
€ 3,288
Supplier invoices still open on the last day of the fiscal year.
€ 12,962
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to SABU PHARMA?
What happened at SABU PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 16,544. Source: NBB ↗
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
Paid € 8,300 in corporate taxes since 2025.
A new publication or filing at SABU PHARMA? We notify you, reason included.
Follow SABU PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind SABU PHARMA is Christ Sabushimike. It owns 40% of Farmacie Henri itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Letterkundestraat 64
2610 Antwerpen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1021.744.847
- VAT number
- BE 1021.744.847
- Registered office
- Letterkundestraat 64, 2610 Antwerpen
- Names & denominations
- SABU PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 April 2025
- Peppol
- Active · Active since 7 Jul 2025
- Activities · NACE
Activiteiten van holdings
Activiteiten van hoofdkantoren
Overige zakelijke dienstverlening, neg
Overige ondersteunende activiteiten in verband met financiële diensten, neg, exclusief verzekeringen en pensioenfondsen